Tech sell-off resumes, counterbalancing bond yield relief; Moderna surges 124% on melanoma vaccine trial results
Tech stocks, particularly semiconductors like Intel, AMD, and Broadcom, faced renewed selling pressure in early trading. This occurred despite falling bond yields, which buoyed the Dow and S&P 500 after the US Treasury Department supported buybacks of long-dated securities. Meanwhile, Moderna shares soared 124% following positive Phase 3 trial results for its melanoma vaccine developed with Merck, driving strength in the healthcare sector. Basic Materials also led the morning, boosted by a surge in gold futures and gold miner stocks.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
US airlines, Microsoft, banks, the NSA, and Apple have suffered consecutive outages, with varying causes and recovery progress
-
2
JPMorgan Chase: ConvaTec Group’s earnings update is expected to dispel market concerns over achieving its 2026 guidance
-
3
UBS expects the renminbi to strengthen to 6.25 per US dollar by the end of 2027.
-
4
CryptoSlate: PEAR Team Reports Simulated Post-Training Model Succeeds 18 Out of 30 Times in Embodied Robotics Tests
-
5
The Korea Herald: Musinsa Standard plans to open its first Jeju Island store on November 26
-
6
South Korea's FSC Plans to Strengthen IT Asset Management and Third-Party Vulnerability Assessments for Financial Institutions
-
7
White House: Trump Announces Over $17 Billion in Commercial Deals and Strategic Investments During Philippines Visit and ASEAN Summit
-
8
CoinDesk: Crypto Basis Trade Yields Near Treasuries, Talos Report Says
-
9
Bloomberg: Indian Tax Officials Considering Proposal to Raise Stock Derivatives Tax and Lower Stock Transaction Tax
-
10
Korean Media: Daewoo E&C discloses delivery of immersed tube tunnel for Al Faw Grand Port to Iraq
Markets Today
Recommended Reading


